Polycythemia Vera News and Research

RSS
TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

IND for Cytopia's CYT387 clears the FDA review

IND for Cytopia's CYT387 clears the FDA review

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Experimental drug successfully blocks mutation in bone marrow cancers

Experimental drug successfully blocks mutation in bone marrow cancers

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Potential new therapy for myeloproliferative disorders

Potential new therapy for myeloproliferative disorders

UIC receives $20 million NCI grant to research blood disorders

UIC receives $20 million NCI grant to research blood disorders

MPD Foundation funds research for incurable blood disorders

MPD Foundation funds research for incurable blood disorders

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Doctors may in future be able to prevent many cases of deep-vein thrombosis

Doctors may in future be able to prevent many cases of deep-vein thrombosis